BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12438271)

  • 21. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model.
    Xing X; Zhang S; Chang JY; Tucker SD; Chen H; Huang L; Hung MC
    Gene Ther; 1998 Nov; 5(11):1538-44. PubMed ID: 9930307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells.
    Gomes EM; Rodrigues MS; Phadke AP; Butcher LD; Starling C; Chen S; Chang D; Hernandez-Alcoceba R; Newman JT; Stone MJ; Tong AW
    Clin Cancer Res; 2009 Feb; 15(4):1317-25. PubMed ID: 19228733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.
    Jing N; Li Y; Xiong W; Sha W; Jing L; Tweardy DJ
    Cancer Res; 2004 Sep; 64(18):6603-9. PubMed ID: 15374974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer therapy utilizing an adenoviral vector expressing only E1A.
    Hubberstey AV; Pavliv M; Parks RJ
    Cancer Gene Ther; 2002 Apr; 9(4):321-9. PubMed ID: 11960282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells.
    Long M; Yin G; Liu L; Lin F; Wang X; Ren J; Wei J; Dong K; Zhang H
    Cancer Gene Ther; 2012 Apr; 19(4):271-81. PubMed ID: 22281755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice.
    Wang WB; Zhou YL; Heng DF; Miao CH; Cao YL
    Breast Cancer Res Treat; 2008 Jul; 110(2):283-95. PubMed ID: 17899369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer.
    Li D; Jiang W; Bishop JS; Ralston R; O'Malley BW
    Clin Cancer Res; 1999 Jun; 5(6):1551-6. PubMed ID: 10389944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
    Lu H; Qin H; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
    Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism.
    Brader KR; Wolf JK; Hung MC; Yu D; Crispens MA; van Golen KL; Price JE
    Clin Cancer Res; 1997 Nov; 3(11):2017-24. PubMed ID: 9815592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
    Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
    Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer.
    Bray D; Yu SZ; Koprowski H; Rhee J; Kumar S; Pericle F; Suntharalingam M; Van Echo DA; Li D; O'Malley BW
    Arch Otolaryngol Head Neck Surg; 2003 Jun; 129(6):618-22. PubMed ID: 12810463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
    Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FasL gene therapy: a new therapeutic modality for head and neck cancer.
    ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS
    Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.